[go: up one dir, main page]

WO2001075079A1 - Nouveau polypeptide, dihydroorotase humaine 13, et polynucleotide codant pour ce polypeptide - Google Patents

Nouveau polypeptide, dihydroorotase humaine 13, et polynucleotide codant pour ce polypeptide Download PDF

Info

Publication number
WO2001075079A1
WO2001075079A1 PCT/CN2001/000361 CN0100361W WO0175079A1 WO 2001075079 A1 WO2001075079 A1 WO 2001075079A1 CN 0100361 W CN0100361 W CN 0100361W WO 0175079 A1 WO0175079 A1 WO 0175079A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
polynucleotide
human dihydroorotase
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2001/000361
Other languages
English (en)
Chinese (zh)
Inventor
Yumin Mao
Yi Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Biowindow Gene Development Inc
Original Assignee
Shanghai Biowindow Gene Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Biowindow Gene Development Inc filed Critical Shanghai Biowindow Gene Development Inc
Priority to AU48240/01A priority Critical patent/AU4824001A/en
Publication of WO2001075079A1 publication Critical patent/WO2001075079A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02003—Dihydroorotase (3.5.2.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Another object of the present invention is to provide mimetic compounds, antagonists, agonists, and inhibitors of the human dihydroorotase 13 of the polypeptide of the present invention.
  • the invention also relates to an isolated polynucleotide comprising a nucleotide sequence or a variant thereof selected from the group consisting of:
  • An "agonist” refers to a molecule that, when combined with human dihydroorotase 13, causes a change in the protein and thereby regulates the activity of the protein.
  • An agonist may include a protein, a nucleic acid, a carbohydrate, or any other molecule that binds human dihydroorotase 13.
  • Derivative refers to a chemical modification of HFP or a nucleic acid encoding it. This chemical modification may be the replacement of a hydrogen atom with an alkyl, acyl or amino group. Nucleic acid derivatives can encode polypeptides that retain the main biological properties of natural molecules.
  • Polynucleotide sequences of the gene of the present invention obtained as described above, or various DNA fragments can be used It is determined by a conventional method such as dideoxy chain termination method (Sanger et al. PNAS, 1977, 74: 5463-5467). Such polynucleotide sequences can also be determined using commercial sequencing kits and the like. In order to obtain the full-length cDNA sequence, sequencing must be repeated. Sometimes it is necessary to determine the cDNA sequence of multiple clones in order to splice into a full-length cDNA sequence.
  • a peptide synthesizer (product of PE company) was used to synthesize the following human dihydroorotase 13-specific peptides:
  • Those that meet the above conditions can be used as primary selection probes, and then further computer sequence analysis, including the primary selection probe and its source sequence region (ie. SEQ ID NO: 1) and other known genomic sequences
  • the column and its complementary region are compared for homology. If the homology with the non-target molecular region is greater than 85% or there are more than 15 consecutive bases, the primary probe should not be used generally
  • human dihydroorotase 1 3 of the present invention will also produce certain hereditary, hematological and immune system diseases.
  • the invention also provides methods for screening compounds to identify agents that increase (agonist) or suppress (antagonist) human dihydroorotase 1 3.
  • Agonists improve human dihydroorotase 1 3 to stimulate biological functions such as cell proliferation, while antagonists prevent and treat disorders related to excessive cell proliferation, such as various cancers.
  • mammalian cells or membrane preparations expressing human dihydroorotase 1 3 can be cultured together with labeled human dihydroorotase 1 3 in the presence of a drug. The ability of the drug to increase or suppress this interaction is then determined.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un nouveau polypeptide, une dihydroorotase humaine 13, et un polynucléotide codant pour ce polypeptide ainsi qu'un procédé d'obtention de ce polypeptide par des techniques recombinantes d'ADN. L'invention concerne en outre les applications de ce polypeptide dans le traitement de maladies, notamment des tumeurs malignes, de l'hémopathie, de l'infection par VIH, de maladies immunitaires et de diverses inflammations. L'invention concerne aussi l'antagoniste agissant contre le polypeptide et son action thérapeutique ainsi que les applications de ce polynucléotide codant pour la dihydroorotase humaine 13.
PCT/CN2001/000361 2000-03-22 2001-03-19 Nouveau polypeptide, dihydroorotase humaine 13, et polynucleotide codant pour ce polypeptide Ceased WO2001075079A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU48240/01A AU4824001A (en) 2000-03-22 2001-03-19 A new polypeptide - human dihydroorotase 13 and the polynucleotide encoding it

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN00115038A CN1314488A (zh) 2000-03-22 2000-03-22 一种新的多肽——人二氢乳清酸酶13和编码这种多肽的多核苷酸
CN00115038.3 2000-03-22

Publications (1)

Publication Number Publication Date
WO2001075079A1 true WO2001075079A1 (fr) 2001-10-11

Family

ID=4584509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2001/000361 Ceased WO2001075079A1 (fr) 2000-03-22 2001-03-19 Nouveau polypeptide, dihydroorotase humaine 13, et polynucleotide codant pour ce polypeptide

Country Status (3)

Country Link
CN (1) CN1314488A (fr)
AU (1) AU4824001A (fr)
WO (1) WO2001075079A1 (fr)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANSARI-LARI M.A. ET AL.: "A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13", GENOME RES., vol. 6, no. 4, 1996, pages 314 - 326 *
CLAVERIE J.M. AND MAKALOWSKI W.: "Alu alert", NATURE, vol. 371, no. 6500, 1994, pages 752 *
HUGHES L.E. ET AL., CURR. MICROBIOL., vol. 39, no. 4, October 1999 (1999-10-01), pages 175 - 179 *
IWAHANA H. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 219, no. 1, 6 February 1996 (1996-02-06), pages 249 - 255 *
JURKA J. AND MILOSAVLJEVIC A.: "Reconstruction and analysis of human Alu genes", J. MOL. EVOL., vol. 32, no. 2, 1991, pages 105 - 121 *
SULSTON J.E. AND WATERSTON R.: "Toward a complete human genome sequence", GENOME RES., vol. 8, no. 11, 1998, pages 1097 - 1108 *

Also Published As

Publication number Publication date
AU4824001A (en) 2001-10-15
CN1314488A (zh) 2001-09-26

Similar Documents

Publication Publication Date Title
WO2002020795A1 (fr) Nouveau polypeptide, hexokinase proteine 9.68, et polynucleotide codant ce polypeptide
WO2001075079A1 (fr) Nouveau polypeptide, dihydroorotase humaine 13, et polynucleotide codant pour ce polypeptide
WO2001070966A1 (fr) Nouveau polypeptide, chaine legere de clathrine humaine 11, et polynucleotide codant pour ce polypeptide
WO2001075023A2 (fr) Nouveau polypeptide, phosphatidylinositol-3 (ptdins 3) kinase humaine 9, et polynucleotide codant pour ce polypeptide
WO2001075048A2 (fr) Nouveau polypeptide, proteine ribosomale humaine s11 23, et polynucleotide codant pour ce polypeptide
WO2001075017A2 (fr) Nouveau polypeptide, dihydroorotase humaine 17, et polynucleotide codant pour ce polypeptide
WO2001073054A1 (fr) Nouveau polypeptide, dihydroorotase humaine 11, et polynucleotide codant pour ce polypeptide
WO2001073061A1 (fr) Nouveau polypeptide, proteine humaine 22 du retinoblastome, et polynucleotide codant pour ce polypeptide
WO2001072810A1 (fr) Nouveau polypeptide, proteine humaine 12 de la famille des amidases, et polynucleotide codant pour ce polypeptide
WO2001083758A2 (fr) Nouveau polypeptide, dihydroorotase humaine 8, et polynucleotide codant pour ce polypeptide
WO2002026795A1 (fr) Nouveau polypeptide, dihydrooratase humaine 15.29, et polynucleotide codant ce polypeptide
WO2001075037A2 (fr) Nouveau polypeptide, dihydroorotase humaine 40, et polynucleotide codant pour ce polypeptide
WO2001085776A1 (fr) Polypeptide humain dihydro-orotase 12 et polynucleotide codant pour ce polypeptide
WO2001070790A1 (fr) Nouveau polypeptide, dihydrooratase humaine 23, et polynucleotide codant pour ce polypeptide
WO2001079435A2 (fr) Nouveau polypeptide, sous-unite humaine 14 de flavoproteine, et polynucleotide codant pour ce polypeptide
WO2001047984A1 (fr) Nouveau polypeptide, proteine 10 de la famille des amidases, et polynucleotide codant pour ce polypeptide
WO2001075024A2 (fr) Nouveau polypeptide, facteur humain 13 associe a nf-e2, et polynucleotide codant pour ce polypeptide
WO2001081592A1 (fr) Nouveau polypeptide, proteine humaine 11 contenant un fragment de sequence particulier d'une signal peptidase i, et polynucleotide codant pour ce polypeptide
WO2001075003A2 (fr) Nouveau polypeptide, protéine humaine d'utérus associé à une molécule cpn 60 26, et polynucléotide codant pour ce polypeptide
WO2001066585A1 (fr) Nouveau polypeptide, proteine humaine 10 regulant la protease, et polynucleotide codant pour ce polypeptide
WO2001090171A1 (fr) Nouveau polypeptide, proteine humaine ribosomale sii 12, et polynucleotide codant ce polypeptide
WO2001072979A1 (fr) Nouveau polypeptide, dihydroorotase humaine 15, et polynucleotide codant pour ce polypeptide
WO2001074885A1 (fr) Nouveau polypeptide, spase i humaine 8, et polynucleotide codant pour ce polypeptide
WO2001075047A2 (fr) Nouveau polypeptide, sous-unite humaine 10 de flavoproteine, et polynucleotide codant pour ce polypeptide
WO2001083724A1 (fr) Nouveau polypeptide, dihydroorotase humaine 17, et polynucleotide codant pour ce polypeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP